Israeli startup AEYE Health announced last week it had received FDA 510(k) clearance for its AI-based screening tool for diabetic retinopathy.
The AEYE-DS system, which received the agency's green light earlier this month, uses images from each eye to detect signs of more-than-mild diabetic retinopathy, a complication from diabetes that can lead to blindness or other serious vision problems.
It'...
